Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Background. Recent studies have demonstrated that measures of health-related quality of life can predict complications and mortality in patients with diabetes, even after adjustment for clinical risk factors. Methods. The authors developed a simulation model of disease progression in type 2 diabetes to investigate the impact of patient quality of life on lifetime outcomes and its potential response to therapy. Changes in health utility over time are captured as a result of complications and aging. All risk equations, model parameter estimates, and input data were derived from patient-level data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial. Results. Healthier patients with type 2 diabetes enjoy more life years, quality-adjusted life years (QALYs), and more life years free of complications. A 65-year-old patient at full health (utility = 1) can expect to live approximately 2 years longer and achieve 6 more QALYs than a patient at average health (utility = 0.8), given similar clinical risk factors. For patients with higher EQ-5D utility, the additional years lived without complications contribute more to longer life expectancy than years lived with complications. Conclusions. The authors have developed a model for progression of disease in diabetes that has a number of novel features; it captures the observed relationships between measures of quality of life and future outcomes, the number of states have been minimized, and it can be parameterized with just 4 risk equations. Underlying the simple model structure is important patient-level heterogeneity in health and outcomes. The simulations suggest that differences in patients' EQ-5D utility can account for large differences in QALYs, which could be relevant in cost-utility analyses.

Original publication

DOI

10.1177/0272989X11409049

Type

Journal article

Journal

Medical Decision Making

Publication Date

01/07/2011

Volume

31

Pages

559 - 570